In accordance with EFPIA’s and PhRMA´s “Principles for Responsible Clinical Trial Date Sharing” guidelines, Lundbeck is committed to responsible sharing of clinical trial data in a manner that is consistent with: safeguarding the privacy of patients, respecting the integrity of national regulatory systems and protecting the intellectual property of the sponsor. The protection of intellectual property ensures continued research and innovation in the pharmaceutical industry.

Lundbeck’s ambition is to improve the quality of life of people living with psychiatric and neurological disorders. As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling this mission. The sharing of clinical trial information will enable the medical and scientific community in the further understanding of the diseases and their treatment for the future benefit of patients.